Efficacy, durability, and safety of intravitreal Faricimab up to every 16 weeks for neovascular age-related macular degeneration: two randomized, double-masked, phase 3, non-inferiority trials.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials – The Lancet (link to abstract – $ for full-text)

Commentary: Trials Show Promise for Intravitreal Faricimab in Retinal Disease – HealthDay